Staphylococcal VaccinePhase 2STRIVENCT02388165
Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation
A Phase 2 study testing Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine in people with Staphylococcal Vaccine, run by Pfizer at 301 sites in 11 countries.
Trial summary
The purposes of the clinical trial are to determine whether the SA4Ag vaccine can prevent postoperative Staphylococcus aureus infections in patients who are undergoing elective spinal fusion surgery, and to evaluate the safety of SA4Ag in patients who are undergoing elective spinal surgery. Read more about this study
- Who is it for?
- Ages 18 to 85 years
- Conditions the study is for
- Staphylococcal Vaccine
- What is being tested?
- Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine
- Type of treatment
- Vaccines, Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 3,450 participants
- Where
- 301 sitesin 11 countries
- Study dates
- 2 Jul 2015to 27 Jun 2019
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Subject must be scheduled to undergo an elective open posterior spinal fusion procedures with multilevel instrumentation, 10 to 60 days after study vaccination.
- Subject must be available for the entire duration of the study, and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures including completion of the electronic diary for 10 days after study vaccination.
- Aged 18 to <86 years old
Who cannot join
- Planned spinal fusion procedure requiring separate operations performed on separate days (ie, staged procedure).
- Surgical indication of malignancy, infection or acute or emergency trauma.
- History of major surgery within 3 months prior to enrollment, or anticipated major surgery other than the Index Surgical Procedure between study enrollment and completion of study participation.
- History of any spinal surgery performed within 6 months prior to study enrollment.
- History of any previous spinal surgery resulting in postoperative BSI or SSI.
- Congenital or acquired immunodeficiency disorder, rheumatologic disorder or other illness requiring chronic treatment with known immunosuppressant medications, including monoclonal antibodies within a year of enrollment or the use of systemic corticosteroids for > 14 days within 30 days prior to enrollment.
- History of leukemia, lymphoma, underlying bone marrow disorder or history of bone marrow transplant.
Trial locations and contacts
301 sites in 11 countries.
301 sites in 11 countries
United States234 sites
Abington Jefferson Health-Pharmacy Department
Abington, Pennsylvania, 19001
Abington Jefferson Health
Abington, Pennsylvania, 19001
University of Michigan Investigational Pharmacy
Ann Arbor, Michigan, 48109-5008
University Of Michigan Hospitals
Ann Arbor, Michigan, 48109-5338
Clinical Alliance for Research and Education - Infectious Diseases, LLC (CARE-ID)
Annandale, Virginia, 22003
AAMC Research Pharmacy
Annapolis, Maryland, 21401
Anne Arundel Health System Research Institute (AAHSRI)
Annapolis, Maryland, 21401
Anne Arundel Medical Center Infusion Center
Annapolis, Maryland, 21401
Anne Arundel Medical Center Laboratory
Annapolis, Maryland, 21401
Anne Arundel Medical Group Orthopedics and Sports Medicine Specialists
Annapolis, Maryland, 21401
Emory University Clinic
Atlanta, Georgia, 30322
Emory Orthopaedics & Spine Center
Atlanta, Georgia, 30329
University of Colorado Clinical & Translational Research Center Clinic
Aurora, Colorado, 80045
University of Colorado Denver, School of Medicine
Aurora, Colorado, 80045
University of Colorado Department of Pharmacy AIP 2, Pharmacy Bulk Storage
Aurora, Colorado, 80045
University of Colorado Hospital
Aurora, Colorado, 80045
Dell Seton Medical Center at The University of Texas
Austin, Texas, 78701
Austin Infectious Disease Consultants
Austin, Texas, 78705
Employee Wellness Center
Austin, Texas, 78705
Seton Medical Center Austin
Austin, Texas, 78705
St. David's Medical Center
Austin, Texas, 78705
St. David's Neuroscience and Spine Institute
Austin, Texas, 78705
Seton Spine and Scoliosis Center
Austin, Texas, 78731
St. David's North Austin Medical Center
Austin, Texas, 78758
Wellness Brain and Spine
Austin, Texas, 78758
University of Maryland Medical Systems, Department of Neurosurgery
Baltimore, Maryland, 21201
University of Maryland Medical Systems, Investigational Drug Services
Baltimore, Maryland, 21201
University of Maryland, Medical Systems, Oriole Park
Baltimore, Maryland, 21201
John Hopkins Bayview Medical Center
Baltimore, Maryland, 21224
Johns Hopkins Bayview Medical Center
Baltimore, Maryland, 21224
Department of Orthopedic Surgery, The Johns Hopkins Outpatient Center
Baltimore, Maryland, 21287
John Hopkins Hospital
Baltimore, Maryland, 21287
The Johns Hopkins Hospital Investigational Drug Service
Baltimore, Maryland, 21287
Clinical Office - Jason Cuellar M.D.
Beverly Hills, California, 90210
The University of Alabama at Birmingham
Birmingham, Alabama, 35294
Bingham Memorial Hospital
Blackfoot, Idaho, 83221
Massachusetts General Hospital, Clinical Research Pharmacy
Boston, Massachusetts, 02114
Massachusetts General Hospital
Boston, Massachusetts, 02114
Brigham and Women's Hospital Investigational Drug Services (IDS)
Boston, Massachusetts, 02115
Brigham and Women's Hospital
Boston, Massachusetts, 02115
Boulder Community Health - Foothills Hospital
Boulder, Colorado, 80303
Boulder Community Health
Boulder, Colorado, 80303
Justin Parker Neurological Institute
Boulder, Colorado, 80303
Anne Arundel Medical Group Orthopedics and Sports Medicine Specialists
Bowie, Maryland, 20716
Rothman Institute-Chalfont Office
Chalfont, Pennsylvania, 18914
Carolina Neurosurgery and Spine Associates, P.A.
Charlotte, North Carolina, 28204
Novant Health Charlotte Orthopedic Hospital/Presbyterian Orthopedic Hospital
Charlotte, North Carolina, 28207
OrthoCarolina Hip & Knee Center
Charlotte, North Carolina, 28207
OrthoCarolina
Charlotte, North Carolina, 28207
OrthoCarolina Pineville
Charlotte, North Carolina, 28210
OrthoCarolina Ballantyne
Charlotte, North Carolina, 28277
University of Virginia Health System
Charlottesville, Virginia, 22903
University of Illinois Hospital and Health Sciences System - Hospital Pharmacy Services
Chicago, Illinois, 60612-4333
University of Illinois Hospital and Health Sciences System
Chicago, Illinois, 60612-7232
Rush University Medical Center (RUMC) / Midwest Orthopedics at Rush University Medical Center (RUMC)
Chicago, Illinois, 60612
Rush University Medical Center Pharmacy
Chicago, Illinois, 60612
Rush University Medical Center Professional Office Building Infusion Pharmacy
Chicago, Illinois, 60612
Rush University Medical Center
Chicago, Illinois, 60612
The Christ Hospital
Cincinnati, Ohio, 45219
The Lindner Center for Research and Education at The Christ Hospital
Cincinnati, Ohio, 45219
Cleveland Clinic Foundation - Investigation Pharmacy
Cleveland, Ohio, 44195
Cleveland Clinic Foundation Center for Spine Health
Cleveland, Ohio, 44195
Riverside Methodist Hospital Pharmacy
Columbus, Ohio, 43214
Remington-Davis, Inc.
Columbus, Ohio, 43215
Orthopedic One
Columbus, Ohio, 43220
Detroit Receiving Hospital, Heart Hospital, Harper Hospital at
Detroit, Michigan, 48201
Dublin Methodist Hospital
Dublin, Ohio, 43016
Duke University Hospital, IDS Pharmacy
Durham, North Carolina, 27710
Duke University Hospital
Durham, North Carolina, 27710
Inova Medical Group
Fairfax, Virginia, 22031
Inova Fair Oaks Hospital
Fairfax, Virginia, 22033
Inova Fairfax Hospital
Falls Church, Virginia, 22042
Inova Neurosciences Research
Falls Church, Virginia, 22042
Neurosurgical Specialist of Texas
Fredericksburg, Texas, 78624
Butterworth Hospital
Grand Rapids, Michigan, 49503
Blodgett Hospital
Grand Rapids, Michigan, 49506
Orthopaedic Associates of Michigan - Research
Grand Rapids, Michigan, 49525
Northwell Health Physician Partners- Department of Neurosurgery Spine @Great Neck
Great Neck, New York, 11021
Milton S. Hershey Medical Center Pharmacy
Hershey, Pennsylvania, 17033
Penn State College of Medicine and Penn State Hershey Milton S. Hershey Medical Center
Hershey, Pennsylvania, 17033
Hermann Drive Surgical Hospital
Houston, Texas, 77004
Mermorial Hermann - Memorial City Medical Center
Houston, Texas, 77024
Baylor College of Medicine - McNair Campus
Houston, Texas, 77030
Baylor College of Medicine
Houston, Texas, 77030
CHI St. Luke's Health Baylor College of Medicine Medical Center
Houston, Texas, 77030
NYU Langone Huntington Medical Group
Huntington Station, New York, 11746
Bingham Memorial Specialty Clinic
Idaho Falls, Idaho, 83404
Brent H. Greenwald, M.D. Neurological Surgery
Idaho Falls, Idaho, 83404
Eastern Idaho Regional Medical Center
Idaho Falls, Idaho, 83404
Mountain View Hospital
Idaho Falls, Idaho, 83404
Snake River Research, PLLC
Idaho Falls, Idaho, 83404
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242
UHS Neurosurgery
Johnson City, New York, 13790
UHS Wilson Medical Center
Johnson City, New York, 13790
Bronson Methodist Hospital
Kalamazoo, Michigan, 49007
Bronson Spine and Scoliosis Specialists
Kalamazoo, Michigan, 49007
University of Kansas Hospital
Kansas City, Kansas, 66103
University of Kansas Medical Center
Kansas City, Kansas, 66160
University Medical Center of Southern Nevada
Las Vegas, Nevada, 89102
University of Colorado Hospital, Lone Tree Health Center
Lone Tree, Colorado, 80124
Memorial Orthopaedic Surgical Group
Long Beach, California, 90806
IDS Pharmacy-USC Norris Comprehensive Cancer Center and Hospital
Los Angeles, California, 90033
Keck Hospital of USC
Los Angeles, California, 90033
USC Spine Center
Los Angeles, California, 90033
USC/Department of Neurological Surgery
Los Angeles, California, 90033
Cedars-Sinai Medical Center - Investigational Drug
Los Angeles, California, 90048
Cedars-Sinai Medical Center
Los Angeles, California, 90048
Clinical Office
Los Angeles, California, 90048
The Spine Center at Cedars-Sinai, Mark Goodson Building, Cedars-Sinai Medical Center
Los Angeles, California, 90048
Ronald Reagan Med Center - University of California, Los Angeles (UCLA)
Los Angeles, California, 90095
Ronald Reagan UCLA Medical Center
Los Angeles, California, 90095
UCLA CTRC Outpatient Unit
Los Angeles, California, 90095
Norton Healthcare Pharmacy
Louisville, Kentucky, 40202
Norton Hospital
Louisville, Kentucky, 40202
Norton Leatherman Spine Center
Louisville, Kentucky, 40202
Northwell Health Physician Partners- Department of Neurosurgery Spine @Lynbrook
Lynbrook, New York, 11563
North Shore University Hospital
Manhasset, New York, 11030
The Feinstein Institute for Medical Research
Manhasset, New York, 11030
The Rothman Institute Marlton, NJ Office
Marlton, New Jersey, 08053
OrthoCarolina Matthews
Matthews, North Carolina, 28105
OrthoVirginia
McLean, Virginia, 22102
Holmes Regional Medical Center
Melbourne, Florida, 32901
The B.A.C.K. Center
Melbourne, Florida, 32901
Melbourne Regional Medical Center
Melbourne, Florida, 32935
University of Miami Hospital and Clinics and Research Pharmacy
Miami, Florida, 33136
University of Miami Hospital
Miami, Florida, 33136
Twin Cities Spine Surgeons dba Twin Cities Spine Center
Minneapolis, Minnesota, 55404
Allina Health - Abbott Northwestern Hospital /
Minneapolis, Minnesota, 55407
HackensackUMC Mountainside Hospital
Montclair, New Jersey, 07042
WVU Medicine Spine Center
Morgantown, West Virginia, 26505
WVU Medicine JW Ruby Memorial Hospital
Morgantown, West Virginia, 26506-9196
WVU Medicine JW Ruby Memorial Hospital In-Patient Pharmacy
Morgantown, West Virginia, 26506
WVU Medicine Physician Office Center Orthopaedic Surgery
Morgantown, West Virginia, 26506
WVU Medicine Physician Office Center
Morgantown, West Virginia, 26506
Meridian Hospitals Corp c/o Jersey Shore University Medical Center
Neptune City, New Jersey, 07753
Yale New Haven Hospital - Investigational Drug Services
New Haven, Connecticut, 06510
Yale New Haven Hospital
New Haven, Connecticut, 06510
Yale New Haven Hospital - St. Raphael campus
New Haven, Connecticut, 06511
Ycci-Csru
New Haven, Connecticut, 06519
Yale-New Haven Hospital Spine Center
New Haven, Connecticut, 06878
Ochsner Baptist Medical Center
New Orleans, Louisiana, 70115
Ochsner Clinic Foundation
New Orleans, Louisiana, 70121
NYU Langone Health Orthopedic Hospital
New York, New York, 10003
Kimmel Pavillion
New York, New York, 10016
NYU Langone Health Orthopedic Center
New York, New York, 10016
NYU Langone Health Tisch Hospital
New York, New York, 10016
NYU Langone Madison Ave. Orthopedics
New York, New York, 10016
Hospital for Special Surgery
New York, New York, 10021
Icahn School of Medicine at Mount Sinai
New York, New York, 10029
lcahn School of Medicine at Mount Sinai
New York, New York, 10029
The Clinical Research Unit at Mount Sinai
New York, New York, 10029
NYU Langone Seaport Orthopaedics
New York, New York, 10279
Ambulatory Care Center
Newark, New Jersey, 07103
Cancer Center, Rutgers, The State University of New Jersey-New Jersey Medical School
Newark, New Jersey, 07103
Doctors Office Center-Rutgers, The State University of New Jersey-New Jersey Medical School
Newark, New Jersey, 07103
University Hospital - Pharmacy
Newark, New Jersey, 07103
University Hospital
Newark, New Jersey, 07103
Sentara Norfolk General Hospital
Norfolk, Virginia, 23507
Sentara Medical Group DBA Sentara Neurosurgery Specialists
Norfolk, Virginia, 23510
Kaiser Permanente Pediatric Clinic
Oakland, California, 94611
Kaiser Permanente Vaccine Study Center
Oakland, California, 94612
Anne Arundel Medical Group Orthopedics and Sports Medicine Specialists
Odenton, Maryland, 21113
University of California Irvine Medical Center
Orange, California, 92868
Florida Hospital Orlando
Orlando, Florida, 32803
Neuroscience ACS Research
Orlando, Florida, 32803
Florida Hospital Orlando - Florida Hospital Investigational Drug Pharmacy
Orlando, Florida, 32804
Anne Arundel Medical Group Orthopedics and Sports Medicine Specialists
Pasadena, Maryland, 21122
Investigational Drug Service Pharmacy
Philadelphia, Pennsylvania, 19107
Jefferson Hospital For Neuroscience
Philadelphia, Pennsylvania, 19107
The Rothman Institute
Philadelphia, Pennsylvania, 19107
Thomas Jefferson University Hospital - Pre-Admission Testing Center
Philadelphia, Pennsylvania, 19107
Thomas Jefferson University Hospital, Cardiovascular Associates
Philadelphia, Pennsylvania, 19107
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, 19107
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107
Barrow Brain and Spine
Phoenix, Arizona, 85013
St. Joseph's Hospital and Medical Center
Phoenix, Arizona, 85013
Allegheny General Hospital
Pittsburgh, Pennsylvania, 15212
Upmc (Puh/Muh)
Pittsburgh, Pennsylvania, 15213
UPMC Presbyterian
Pittsburgh, Pennsylvania, 15213
Baylor Scott & White Medical Center
Plano, Texas, 75093
Physicians & Surgeons Clinic
Pocatello, Idaho, 83201
Bingham Memorial Family Medicine & Specialty Clinic
Pocatello, Idaho, 83202
OHSU Research Pharmacy
Portland, Oregon, 97239
Oregon Health and Sciences University
Portland, Oregon, 97239
VCU Medical Center Investigational Drug Service
Richamond, Virginia, 23298-5028
VCU Heatlh Neuroscience Orthopedic and Wellness Center
Richmond, Virginia, 23233
VCU Health Ambulatory Care Center
Richmond, Virginia, 23298
VCU Health
Richmond, Virginia, 23298
Carilion Assessment, Registration and Education for Surgery (C.A.R.E.S)
Roanoke, Virginia, 24014
Carilion Clinic - Department of Pharmacy
Roanoke, Virginia, 24014
Carilion Clinic Institute for Orthopaedics and Neurosciences
Roanoke, Virginia, 24014
Carilion Roanoke Memorial Hospital
Roanoke, Virginia, 24014
Carilion Clinic Riverside 3
Roanoke, Virginia, 24016
Mayo Clinic Hospital, Methodist Campus
Rochester, Minnesota, 55902
Mayo Clinic Rochester, Methodist Hospital Campus
Rochester, Minnesota, 55902
Mayo Clinic Hospital, Methodist Campus
Rochester, Minnesota, 55905
Mayo Clinic
Rochester, Minnesota, 55905
Michigan Orthopaedic & Spine Surgeons
Rochester Hills, Michigan, 48307
Seton Brain and Spine Institute Williamson
Round Rock, Texas, 78665
Seton Medical Center Williamson
Round Rock, Texas, 78665
St. David's Round Rock Medical Center
Round Rock, Texas, 78681
Beaumont Orthopaedic Center
Royal Oak, Michigan, 48073
William Beaumont Hospital
Royal Oak, Michigan, 48073
University of California, San Francisco
San Francisco, California, 94143
UCLA Spine Center
Santa Monica, California, 90401
Santa Monica UCLA Medical Center & Orthopaedic Hospital
Santa Monica, California, 90404
UCLA Santa Monica Infectious Disease
Santa Monica, California, 90404
Gulfcoast Research Institute, LLC
Sarasota, Florida, 34232
Greenbaum Surgical Specialty Hospital
Scottsdale, Arizona, 85251
HonorHealth Scottsdale Osborn Medical Center
Scottsdale, Arizona, 85251
Virginia Mason Medical Center
Seattle, Washington, 98101
The Rothman Institute Washington Township, NJ Office
Sewell, New Jersey, 08080
Spine Institute of Louisiana
Shreveport, Louisiana, 71101-4643
Michigan Orthopaedic Institute
Southfield, Michigan, 48033
Center for Outpatient Health
St Louis, Missouri, 63108
Barnes Jewish Center for Advanced Medicine
St Louis, Missouri, 63110
Barnes Jewish Hospital
St Louis, Missouri, 63110
Barnes Jewish Pharmacy
St Louis, Missouri, 63110
Barnes-Jewish Pharmacy
St Louis, Missouri, 63110
Washington University
St Louis, Missouri, 63110
Scott & White Memorial Hospital and Clinic (Scott & White Roney Bone & Joint Institute)
Temple, Texas, 76508
Scott & White Memorial Hospital and Clinic
Temple, Texas, 76508
Scott & White Memorial Hospital
Temple, Texas, 76508
LA BioMed at Harbor-UCLA Medical Center
Torrance, California, 90502
LA BioMed, Harbor-UCLA Medical Center
Torrance, California, 90502
Harbor-UCLA Medical Center
Torrance, California, 90509
LA BioMed at Harbor-UCLA Medical Center
Torrance, California, 90509
Beaumont Health-Troy
Troy, Michigan, 48085
Emory Orthopaedics & Spine Hospital
Tucker, Georgia, 30084
Michigan Orthopaedic Institute
West Bloomfield, Michigan, 48322
Rothman Institute-Willow Grove Office
Willow Grove, Pennsylvania, 19090
UMass Memorial Medical Center- Clinical Research Center
Worcester, Massachusetts, 01605
UMass Memorial Medical Center
Worcester, Massachusetts, 01605
University of Massachusetts Medical Center Memorial Campus
Worcester, Massachusetts, 01605
France19 sites
CHU Pellegrin Tripode
Bordeaux, 33076
CHU Pellegrin, Pharmacie
Bordeaux, 33076
CHU de Dijon
Dijon, 21000
CHU de Dijon
Dijon, 21079
CHU Hopital d'Enfants
Dijon, 21079
AP-HM La Timone - Hopital adultes
Marseille, 13385
AP-HM Hopital Nord
Marseille, 13915
CHU de Nantes - Hotel Dieu
Nantes, 44093
CHU de Nimes - Caremeau
Nîmes, 30029
CHU de Nimes
Nîmes, 30029
CIC Cochin/Pasteur (CIC 1417)
Paris, 75014
Service de Chirurgie Orthopedique et Traumatologie
Paris, 75014
Service de Pharmacie
Paris, 75014
CHU de Rennes - Hopital Pontchaillou
Rennes, 35033
CHU de Rennes
Rennes, 35033
Unite d'investigation clinique
Rennes, 35033
Hopital Nord-CHU Saint Etienne
Saint-Priest-en-Jarez, 42270
Hopital Civil
Strasbourg, 67091
Hopitaux Universitaires de Strasbourg
Strasbourg, 67200
Canada10 sites
Foothills Medical Centre
Calgary, Alberta, T2N 2T9
Foothills Medical Centre, University of Calgary
Calgary, Alberta, T2N 4Z6
Montreal Neurological Hospital Research Pharmacy
Montreal, Quebec, H3A 2B4
Montreal Neurological Institute and Hospital
Montreal, Quebec, H3A 2B4
Montreal General Hospital Research Institute of the MUHC- MGH Pharmacy Research
Montreal, Quebec, H3G 1A4
The Ottawa Hospital, Civic Campus
Ottawa, Ontario, K1Y 4E9
St. Michael's Hospital
Toronto, Ontario, M5B 1M4
St, Michael's Hospital - St. Michael's Pharmacy
Toronto, Ontario, M5B 1W8
St. Michael's Hospital
Toronto, Ontario, M5B 1W8
Toronto Western Hospital
Toronto, Ontario, M5T 2S8
Japan10 sites
Hakodate Central General Hospital
Hakodate, Hokkaido, 040-8585
Seirei Hamamatsu General Hospital
Hamamatsu, Shizuoka, 430-8558
Saiseikai Kawaguchi General Hospital
Kawaguchi, Saitama, 332-8558
Japan Organization of Occupational Health and Safety, Kanto Rosai Hospital
Kawasaki, Kanagawa, 211-8510
National Hospital Organization Murayama Medical Center
Musashimurayama, Tokyo, 208-0011
Musashino Red Cross Hospital
Musashino, Tokyo, 180-8610
Japan Community Health care Organization Osaka Hospital
Osaka, 553-0003
National Hospital Organization Hokkaido Medical Center
Sapporo, Hokkaido, 063-0005
Nagasaki Rosai Hospital
Sasebo, Nagasaki, 857-0134
Shimonoseki City Hospital
Shimonoseki-shi, Yamaguchi, 750-8520
Spain10 sites
Hospital Universitario Fundacion Alcorcon
Alcorcón, Madrid, 28922
Hospital Universitari Germans Trias i Pujol
Badalona, Barcelona, 08916
Hospital Universitari Vall d'Hebron
Barcelona, 08035
Hospital Clinic de Barcelona
Barcelona, 08036
Hospital Ramon Y Cajal
Madrid, 28034
Hospital Clínico Universitario Santiago de Compostela
Santiago de Compostela, A Coruna, 15706
Hospital Universitario Virgen del Rocio
Seville, 41013
Hospital Universitario Politecnico La Fe
Valencia, 46026
Pharmacy Service of Hospital Clinico de Valladolid
Valladolid, 47003
Hospital Clinico Universitario de Valladolid
Valladolid, 47005
United Kingdom7 sites
Pharmacy Store, Main Pharmacy
Middlesbrough, Cleveland, TS4 3BW
Pharmacy Store
Middlesbrough, Cleveland, TS4 3BW
South Tees Hospitals NHS Foundation Trust
Middlesbrough, Cleveland, TS4 3BW
The James Cook University Hospital
Middlesbrough, Cleveland, TS4 3BW
Centre for Spinal Studies and Surgery
Nottingham, NG7 2UH
Salford Royal NHS Foundation Trust
Salford, Greater Manchester, M6 8HD
Southampton General Hospital
Southampton, SO16 6YD
Germany6 sites
Charite- University Medicine Berlin
Berlin, 10117
Charite- University Medicine Berlin
Berlin, 13353
Uniklinik Koeln
Cologne, 50937
Klinikum rechts der Isar, Technische Universitat Munchen
München, 81675
Klinikum rechts der Isar
München, 81675
St. Franziskus Hospital Munster
Münster, 48415
Austria2 sites
Tirol Kliniken GmbH
Innsbruck, 6020
Tirol Kliniken
Innsbruck, 6020
About this study
Official title: A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF STAPHYLOCOCCUS AUREUS 4 ANTIGEN VACCINE (SA4AG) IN ADULTS UNDERGOING ELECTIVE OPEN POSTERIOR SPINAL FUSION PROCEDURES WITH MULTILEVEL INSTRUMENTATION
The purposes of the clinical trial are to determine whether the SA4Ag vaccine can prevent postoperative Staphylococcus aureus infections in patients who are undergoing elective spinal fusion surgery, and to evaluate the safety of SA4Ag in patients who are undergoing elective spinal surgery.
- Conditions
- Staphylococcal Vaccine
- Being tested
- Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine, Placebo
- Keywords
- Staphylococcal Vaccine, Post-operative Surgical Site Infection, Spinal Surgery, MRSA, Staphylococcus aureus
- Medical subject headings
- Staphylococcal Infections
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Staphylococcus aureus 4-Antigen (SA4Ag) VaccineBiological
Also called Vaccine
SA4Ag vaccine reconstituted in 0.5mL water for injection. Administered via IM injection, once 10 to 60 days prior to surgery
PlaceboOther
Vaccine excipients reconstituted in 0.5mL water for injections. Administered via IM injection given 10 to 60 days prior to surgery
| Study group | Role | What they receive |
|---|---|---|
| SA4Ag | Active comparator | Staphylococcus aureus 4-antigen Vaccine Receives: Biological: Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine |
| Placebo | Placebo comparator | Diluent (sterile water) for Placebo Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants With Postoperative Staphylococcus (S.) Aureus Bloodstream Infection (BSI) And/or Surgical-site Infection (SSI-Including Deep Incisional or Organ/Space) Occurred Within 90 Days After Spinal Surgery
BSI: clinical infection involved a recognized pathogen (S. aureus) cultured from 1 or more blood cultures or a commensal organism cultured from 2 or more blood cultures whether primary or secondary to infection at another site. SSI: infection at a surgical incision. Types of SSI in this outcome measure: Deep incisional SSI: infection involved deep soft tissues of incision (example [e.g.] fascial and muscle layers), Organ/space SSI: infection involved any part of body excluding skin incision, fascia or muscle layers, that was opened or manipulated during operative procedure. Overall number of participants with postoperative BSI and/or SSI (including deep incisional or organ/space), caused by S. aureus, occurred within 90 days of post elective open posterior spinal fusion surgery with multilevel instrumentation, as confirmed by event adjudication committee (EAC) have been reported. A participant may have met criteria for both BSI and SSI (deep incisional or organ/space).
Measured: Day of surgery (Day 1) up to Day 90
Percentage of Participants With Local Reactions Within 10 Days After Vaccination
Local reactions were recorded using an electronic diary (e-diary). Local reactions included redness, swelling and pain at the injection site. Redness and swelling were categorized as mild (2.5 to 5.0 centimeters [cm]), moderate (5.5 to 10.0 cm) and, severe (greater than or equal to [>=] 10.5 cm). Pain at the injection site was defined as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity). Participants may be represented in more than 1 row. Here, "Any" for redness, swelling, pain at the injection site represents any grade of these local reactions among mild, moderate or severe.
Measured: Within 10 days after Vaccination
Percentage of Participants With Systemic Reactions Within 10 Days After Vaccination
Systemic reactions included fever, fatigue, headache, diarrhea, vomiting, muscle pain and joint pain, were recorded using an e-diary. Fever was graded as 38.0 to 38.4 degree Celsius (C), 38.5 to 38.9 degree C, 39.0 to 40.0 degree C and greater than (>) 40.0 degree C. Vomiting was graded as mild (1-2 times in 24 hours), moderate (>2 times in 24 hours) and severe (required intravenous hydration). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours) and severe (>=6 loose stools in 24 hours). Headache, fatigue, muscle pain and joint pain were graded as mild (no interference with activity), moderate (some interference with activity) and severe (prevented daily routine activity). Participants may be represented in more than 1 row. Here "any" for fever, fatigue, headache, vomiting, diarrhea, muscle pain, joint pain represents any grade of these systemic reactions among mild, moderate or severe.
Measured: Within 10 days after Vaccination
Number of Participants With Adverse Events (AEs) From Vaccination Until The Day of Surgery (Day 1)
An adverse event (AE) was any untoward medical occurrence in a participant who received study vaccine without regard to possibility of causal relationship. AEs including serious as well non-serious AEs.
Measured: From vaccination up to Day of surgery (Day 1) (10-60 days after vaccination)
Number of Participants With Adverse Events (AEs) From Vaccination Until First Postoperative Evaluation on Day 42
An AE was any untoward medical occurrence in a participant who received study vaccine without regard to possibility of causal relationship. AEs including serious as well non-serious AEs.
Measured: From vaccination until Day 42 after surgery (52-102 days after vaccination)
Number of Participants With Adverse Events (AEs) From The Day of Surgery (Day 1) Until First Postoperative Evaluation on Day 42
An AE was any untoward medical occurrence in a participant who received study vaccine without regard to possibility of causal relationship. AEs including serious as well non-serious AEs.
Measured: Day of surgery (Day 1) up to Day 42 after surgery
Number of Participants With Newly Diagnosed Chronic Medical Disorders From First Postoperative Evaluation on Day 42 Until Last Postoperative Evaluation on Day 180
A newly diagnosed chronic medical disorder was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
Measured: Day 42 up to Day 180 (up to 138 days)
Number of Participants With Serious Adverse Events (SAEs) From Vaccination Until Last Postoperative Evaluation on Day 180
An AE was any untoward medical occurrence in a participant who received study vaccine without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability/incapacity, congenital anomaly.
Measured: From vaccination up to Day 180 after surgery (190-240 days after vaccination)
Number of Participants With Serious Adverse Events (SAEs) From Vaccination Until Day of Surgery (Day 1)
An AE was any untoward medical occurrence in a participant who received study vaccine without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability/incapacity, congenital anomaly.
Measured: From vaccination up to Day of surgery (Day 1) (10-60 days after vaccination)
Number of Participants With Serious Adverse Events (SAEs) From The Day of Surgery (Day 1) Until Last Postoperative Evaluation on Day 180
An AE was any untoward medical occurrence in a participant who received study vaccine without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability/incapacity, congenital anomaly.
Measured: Day of surgery (Day 1) up to Day 180 after surgery
Secondary outcomes (3)
Number of Participants With Postoperative S. Aureus Blood Stream Infection (BSI) And/or Surgical-site Infection (SSI-Including Deep Incisional or Organ/Space) Occurred Within 180 Days After Surgery
BSI: clinical infection involved a recognized pathogen (S. aureus) cultured from 1 or more blood cultures or a commensal organism cultured from 2 or more blood cultures whether primary or secondary to infection at another site. SSI: infection at a surgical incision. Types of SSI in this outcome measure: Deep incisional SSI: infection involved deep soft tissues of incision (e.g. fascial and muscle layers), Organ/space SSI: infection involved any part of body excluding skin incision, fascia or muscle layers, that was opened or manipulated during operative procedure. Overall number of participants with postoperative BSI and/or SSI (including deep incisional or organ/space), caused by S. aureus, occurred within 180 days of post elective open posterior spinal fusion surgery with multilevel instrumentation, as confirmed by EAC have been reported. A participant may have met criteria for both BSI and SSI (deep incisional or organ/space).
Measured: Day of surgery (Day 1) up to Day 180 after surgery
Number of Participants With Any Postoperative S. Aureus Surgical-site Infection (SSI-Superficial, Deep Incisional or Organ/Space) Occurred Within 90 Days After Surgery
SSI: infection at a surgical incision. Types of SSI in this outcome measure: Superficial SSI: Infection involved only skin and subcutaneous tissue of the incision, Deep incisional SSI: infection involved deep soft tissues of incision (e.g. fascial and muscle layers), Organ/space SSI: infection involved any part of body, excluding skin incision, fascia, or muscle layers, that was opened or manipulated during operative procedure. Overall number of participants with postoperative SSI (including superficial, deep incisional and/or organ/space SSI) caused by S. aureus, occurred within 90 days after elective open posterior spinal fusion surgery with multilevel instrumentation as confirmed by EAC have been reported.
Measured: Day of surgery (Day 1) up to Day 90 after surgery
Number of Participants With Any Postoperative S. Aureus Surgical-site Infection (SSI-Superficial, Deep Incisional or Organ/Space) Occurred Within 180 Days After Surgery
SSI: infection at a surgical incision. Types of SSI in this outcome measure: Superficial SSI: Infection involved only skin and subcutaneous tissue of the incision, Deep incisional SSI: infection involved deep soft tissues of incision (e.g. fascial and muscle layers), Organ/space SSI: infection involved any part of body, excluding skin incision, fascia, or muscle layers, that was opened or manipulated during operative procedure. Overall number of participants with postoperative SSI (including superficial, deep incisional and/or organ/space SSI) caused by S. aureus, occurred within 180 days after elective open posterior spinal fusion surgery with multilevel instrumentation as confirmed by EAC have been reported.
Measured: Day of surgery (Day 1) up to Day 180 after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Mar 2015 (estimated)
- Study start2 Jul 2015
- Primary completion26 Jun 2019
- Study completion27 Jun 2019
Why it stopped: Study terminated by sponsor
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Staphylococcal VaccineStudies of the same condition, open and under way.
- More trials run by PfizerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 3,450 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pfizer
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02388165
- Sponsor's protocol ID
- B3451002
- Other IDs
- 2014-002644-40, 6123K1-2001, STRIVE, 2014
- Acronym
- STRIVE
- Status last verified
- Nov 2020
- First submitted
- 9 Mar 2015
- Last updated
- 5 Jan 2021
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.
Publications
Hassanzadeh H, Baber J, Begier E, Noriega DC, Konishi H, Yato Y, Wang MY, Le Huec JC, Patel V, Varga P, Liljenqvist U, Conly J, Sabharwal C, Munjal I, Cooper D, Radley D, Jaques A, Patton M, Gruber WC, Jansen KU, Anderson AS, Gurtman A; STaphylococcus aureus suRgical Inpatient Vaccine Efficacy Investigator Team. Efficacy of a 4-Antigen Staphylococcus aureus Vaccine in Spinal Surgery: The STaphylococcus aureus suRgical Inpatient Vaccine Efficacy (STRIVE) Randomized Clinical Trial. Clin Infect Dis. 2023 Jul 26;77(2):312-320. doi: 10.1093/cid/ciad218.
PubMed 37125490
Study at a glance
From the registry record, last updated by the sponsor on 5 Jan 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF STAPHYLOCOCCUS AUREUS 4 ANTIGEN VACCINE (SA4AG) IN ADULTS UNDERGOING ELECTIVE OPEN POSTERIOR SPINAL FUSION PROCEDURES WITH MULTILEVEL INSTRUMENTATION
- ClinicalTrials.gov ID
- NCT02388165
- Acronym / sponsor ID
- STRIVE / B3451002
- Conditions
- Staphylococcal Vaccine
- Keywords
- Staphylococcal Vaccine, Post-operative Surgical Site Infection, Spinal Surgery, MRSA, Staphylococcus aureus
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Study terminated by sponsor
- Enrolment
- 3,450 participants (actual)
- Lead sponsor
- PfizerIndustry (pharma, biotech, devices)
- Study start
- 2 Jul 2015 (actual)
- Primary completion
- 26 Jun 2019 (actual)
- Study completion
- 27 Jun 2019 (actual)
- First posted
- 13 Mar 2015 (estimated)
- Results
- Posted 2 Sep 2020
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purposes of the clinical trial are to determine whether the SA4Ag vaccine can prevent postoperative Staphylococcus aureus infections in patients who are undergoing elective spinal fusion surgery, and to evaluate the safety of SA4Ag in patients who are undergoing elective spinal surgery.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| SA4Ag | Active comparator | Biological: Staphylococcus aureus 4-Antigen (SA4Ag) VaccineStaphylococcus aureus 4-antigen Vaccine |
| Placebo | Placebo comparator | Other: PlaceboDiluent (sterile water) for Placebo |
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Subject must be scheduled to undergo an elective open posterior spinal fusion procedures with multilevel instrumentation, 10 to 60 days after study vaccination.
- Subject must be available for the entire duration of the study, and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures including completion of the electronic diary for 10 days after study vaccination.
- Aged 18 to <86 years old
Key exclusion criteria (7 listed)
- Planned spinal fusion procedure requiring separate operations performed on separate days (ie, staged procedure).
- Surgical indication of malignancy, infection or acute or emergency trauma.
- History of major surgery within 3 months prior to enrollment, or anticipated major surgery other than the Index Surgical Procedure between study enrollment and completion of study participation.
- History of any spinal surgery performed within 6 months prior to study enrollment.
- History of any previous spinal surgery resulting in postoperative BSI or SSI.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Staphylococcus aureus 4-Antigen (SA4Ag) VaccineAlso: VaccineSA4Ag vaccine reconstituted in 0.5mL water for injection. Administered via IM injection, once 10 to 60 days prior to surgery | Biological | SA4Ag |
| PlaceboVaccine excipients reconstituted in 0.5mL water for injections. Administered via IM injection given 10 to 60 days prior to surgery | Other | Placebo |
Primary outcome
Number of Participants With Postoperative Staphylococcus (S.) Aureus Bloodstream Infection (BSI) And/or Surgical-site Infection (SSI-Including Deep Incisional or Organ/Space) Occurred Within 90 Days After Spinal Surgery
Time frame: Day of surgery (Day 1) up to Day 90
BSI: clinical infection involved a recognized pathogen (S. aureus) cultured from 1 or more blood cultures or a commensal organism cultured from 2 or more blood cultures whether primary or secondary to infection at another site. SSI: infection at a surgical incision. Types of SSI in this outcome measure: Deep incisional SSI: infection involved deep soft tissues of incision (example [e.g.] fascial and muscle layers), Organ/space SSI: infection involved any part of body excluding skin incision, fascia or muscle layers, that was opened or manipulated during operative procedure. Overall number of participants with postoperative BSI and/or SSI (including deep incisional or organ/space), caused by S. aureus, occurred within 90 days of post elective open posterior spinal fusion surgery with multilevel instrumentation, as confirmed by event adjudication committee (EAC) have been reported. A participant may have met criteria for both BSI and SSI (deep incisional or organ/space).
Percentage of Participants With Local Reactions Within 10 Days After Vaccination
Time frame: Within 10 days after Vaccination
Local reactions were recorded using an electronic diary (e-diary). Local reactions included redness, swelling and pain at the injection site. Redness and swelling were categorized as mild (2.5 to 5.0 centimeters [cm]), moderate (5.5 to 10.0 cm) and, severe (greater than or equal to [>=] 10.5 cm). Pain at the injection site was defined as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity). Participants may be represented in more than 1 row. Here, "Any" for redness, swelling, pain at the injection site represents any grade of these local reactions among mild, moderate or severe.
Percentage of Participants With Systemic Reactions Within 10 Days After Vaccination
Time frame: Within 10 days after Vaccination
Systemic reactions included fever, fatigue, headache, diarrhea, vomiting, muscle pain and joint pain, were recorded using an e-diary. Fever was graded as 38.0 to 38.4 degree Celsius (C), 38.5 to 38.9 degree C, 39.0 to 40.0 degree C and greater than (>) 40.0 degree C. Vomiting was graded as mild (1-2 times in 24 hours), moderate (>2 times in 24 hours) and severe (required intravenous hydration). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours) and severe (>=6 loose stools in 24 hours). Headache, fatigue, muscle pain and joint pain were graded as mild (no interference with activity), moderate (some interference with activity) and severe (prevented daily routine activity). Participants may be represented in more than 1 row. Here "any" for fever, fatigue, headache, vomiting, diarrhea, muscle pain, joint pain represents any grade of these systemic reactions among mild, moderate or severe.
Number of Participants With Adverse Events (AEs) From Vaccination Until The Day of Surgery (Day 1)
Time frame: From vaccination up to Day of surgery (Day 1) (10-60 days after vaccination)
An adverse event (AE) was any untoward medical occurrence in a participant who received study vaccine without regard to possibility of causal relationship. AEs including serious as well non-serious AEs.
Number of Participants With Adverse Events (AEs) From Vaccination Until First Postoperative Evaluation on Day 42
Time frame: From vaccination until Day 42 after surgery (52-102 days after vaccination)
An AE was any untoward medical occurrence in a participant who received study vaccine without regard to possibility of causal relationship. AEs including serious as well non-serious AEs.
Number of Participants With Adverse Events (AEs) From The Day of Surgery (Day 1) Until First Postoperative Evaluation on Day 42
Time frame: Day of surgery (Day 1) up to Day 42 after surgery
An AE was any untoward medical occurrence in a participant who received study vaccine without regard to possibility of causal relationship. AEs including serious as well non-serious AEs.
Number of Participants With Newly Diagnosed Chronic Medical Disorders From First Postoperative Evaluation on Day 42 Until Last Postoperative Evaluation on Day 180
Time frame: Day 42 up to Day 180 (up to 138 days)
A newly diagnosed chronic medical disorder was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
Number of Participants With Serious Adverse Events (SAEs) From Vaccination Until Last Postoperative Evaluation on Day 180
Time frame: From vaccination up to Day 180 after surgery (190-240 days after vaccination)
An AE was any untoward medical occurrence in a participant who received study vaccine without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability/incapacity, congenital anomaly.
Number of Participants With Serious Adverse Events (SAEs) From Vaccination Until Day of Surgery (Day 1)
Time frame: From vaccination up to Day of surgery (Day 1) (10-60 days after vaccination)
An AE was any untoward medical occurrence in a participant who received study vaccine without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability/incapacity, congenital anomaly.
Number of Participants With Serious Adverse Events (SAEs) From The Day of Surgery (Day 1) Until Last Postoperative Evaluation on Day 180
Time frame: Day of surgery (Day 1) up to Day 180 after surgery
An AE was any untoward medical occurrence in a participant who received study vaccine without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability/incapacity, congenital anomaly.
3 secondary outcomes
Number of Participants With Postoperative S. Aureus Blood Stream Infection (BSI) And/or Surgical-site Infection (SSI-Including Deep Incisional or Organ/Space) Occurred Within 180 Days After Surgery
Time frame: Day of surgery (Day 1) up to Day 180 after surgery
Number of Participants With Any Postoperative S. Aureus Surgical-site Infection (SSI-Superficial, Deep Incisional or Organ/Space) Occurred Within 90 Days After Surgery
Time frame: Day of surgery (Day 1) up to Day 90 after surgery
Number of Participants With Any Postoperative S. Aureus Surgical-site Infection (SSI-Superficial, Deep Incisional or Organ/Space) Occurred Within 180 Days After Surgery
Time frame: Day of surgery (Day 1) up to Day 180 after surgery
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Jan 2021.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 37125490Hassanzadeh H, Baber J, Begier E, Noriega DC, Konishi H, Yato Y, Wang MY, Le Huec JC, Patel V, Varga P, Liljenqvist U, Conly J, Sabharwal C, Munjal I, Cooper D, Radley D, Jaques A, Patton M, Gruber WC, Jansen KU, Anderson AS, Gurtman A; STaphylococcus aureus suRgical Inpatient Vaccine Efficacy Investigator Team. Efficacy of a 4-Antigen Staphylococcus aureus Vaccine in Spinal Surgery: The STaphylococcus aureus suRgical Inpatient Vaccine Efficacy (STRIVE) Randomized Clinical Trial. Clin Infect Dis. 2023 Jul 26;77(2):312-320. doi: 10.1093/cid/ciad218.
- To obtain contact information for a study center near you, click here.Link provided by the sponsor.
- Individual participant dataSharing planned: Yes. Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pfizer CT.gov Call Center study director
Pfizer
301 sites in 11 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine in people with Staphylococcal Vaccine, run by Pfizer at 301 sites in 11 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 5 Jan 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 301 sites in United States, France, Canada, Japan, Spain and 6 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 2 Sep 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants With Postoperative Staphylococcus (S.) Aureus Bloodstream Infection (BSI) And/or Surgical-site Infection (SSI-Including Deep Incisional or Organ/Space) Occurred Within 90 Days After Spinal Surgery (time frame: Day of surgery (Day 1) up to Day 90). The study lists 10 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02388165, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jan 2021.